Abstract 5788: Genomic and transcriptomic profiles of DNA damage response genes in acute myeloid leukemia
Antonella Padella(University of Bologna), Torsten Haferlach(Martin Luther Christian University), Claudia Haferlach(Munich Leukemia Laboratory (Germany)), Martina Ghetti(Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori), Constance Baer(Munich Leukemia Laboratory (Germany)), Wolfgang Kern(Munich Leukemia Laboratory (Germany)), Giorgia Simonetti(Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori), Wencke Walter(Munich Leukemia Laboratory (Germany)), Stephan Hütter(Munich Leukemia Laboratory (Germany)), Giovanni Martinelli(University of Bologna), Irene Azzali(Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori), Lorenzo Ledda(Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori), Matteo Paganelli(Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori), Andrea Ghelli Luserna di Rorà(Fondazione Pisa)
Cited by 0
Related Papers
Gilteritinib or Chemotherapy for Relapsed or Refractory <i>FLT3</i> -Mutated AML
|New England Journal of Medicine|2019|1.3k
International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts
|Blood|2015|1.2k
Minimal/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party
|Blood|2018|1k
2021 Update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD Working Party
|Blood|2021|714
Levofloxacin to Prevent Bacterial Infection in Patients with Cancer and Neutropenia
|New England Journal of Medicine|2005|644